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Abstract
Objective—To investigate the relationship between spina bifida and two established risk factors, 
pregestational diabetes and obesity, in both the presence and absence of the recommended daily 
folic acid intake in the periconceptional period.
Study Design—Cases of spina bifida (n=1154) and controls (n=9439) from the Slone 
Epidemiology Center Birth Defects Study (1976–2011) were included. Information on preexisting 
diabetes (collected 1976+) and obesity (collected 1993+), defined as BMI ≥30 kg/m2, were 
collected through interviews conducted within six months of delivery. Periconceptional folic acid 
intake was calculated using both dietary and supplement information. Mothers were classified as 
consuming more or less than 400µg/day of folic acid, with food folate included at a 30% discount 
for its lower bioavailability. Logistic regression models, adjusted for maternal race, education, and 
study site, were used to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI) for 
the joint effects of low folic acid intake coupled with diabetes or obesity.
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Results—Mothers of cases were more likely to have diabetes or be obese (0.7% and 19.0%, 
respectively) than control mothers (0.4% and 10.8%, respectively). The joint effect of diabetes and 
lower folic acid intake on spina bifida was larger (aOR:3.95; CI: 1.56, 10.00) than that of diabetes 
and higher folic acid intake (aOR:1.31; CI: 0.17, 10.30). Folic acid intake made little difference on 
the association between obesity and spina bifida.
Conclusion—Our findings suggest that folic acid further attenuates, though does not eliminate, 
the risk of spina bifida associated with diabetes, than that with obesity.
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Introduction
Folic acid intake in the periconceptional period reduces the risk of spina bifida in 
offspring1–4. Spina bifida, a neural tube defect, develops in the earliest part of pregnancy, 
frequently prior to recognition of pregnancy. Due to this early developmental timing and the 
fact that approximately half of all pregnancies in the United States are unplanned5, the 
United States Public Health Service, the Institute of Medicine6, and the United States 
Preventive Services Task Force7 recommend that women of child-bearing age consume at 
least 400µg of folic acid daily through supplements and fortified food products8. Despite 
these recommendations and mandatory fortification of enriched cereal grain products 
beginning in the U.S. in 1998, a recent study estimated that only one in four women of 
child-bearing age consumes the recommended amount of folic acid9. Given the established 
role of folic acid in reducing the occurrence of spina bifida, it is possible that risk factors for 
spina bifida may operate differently in the presence and absence of folic acid.
Preexisting diabetes and obesity have both been identified as independent risk factors for 
spina bifida10–13, yet few studies have addressed the impact of folic acid intake on these 
associations. In animal studies, folic acid supplementation has been shown to decrease the 
incidence of neural tube defects among diabetic pregnancies14,15. The only epidemiologic 
study conducted to date observed that diabetic women using folic acid-containing 
supplements had a lower risk of spina bifida than non-supplementing diabetic women16. 
Similarities in the physiology of diabetes and obesity, including abnormalities in glucose 
metabolism, might suggest that folic acid may also affect the association between obesity 
and spina bifida. A studyof prepregnancy weight and neural tube defects observed that folic 
acid offered some protection among lighter women (<70 kg), but no such protection among 
heavier women17.
With recent studies suggesting that, in the era of folic acid fortification, achieving higher 
levels of folic acid intake through supplement use18,19 and dietary folate19 may not reduce 
the risk of neural tube defects, it is important to understand if higher levels of folic acid 
intake alter the effect of other risk factors for spina bifida. Using data from the Slone 
Epidemiology Center Birth Defects Study, we sought to describe the effect of obesity and 
diabetes on the risk of spina bifida in both the presence and absence of the recommended 
amount of daily folic acid intake.
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Materials and Methods
Study Population
The Slone Epidemiology Center Birth Defects Study is an on-going case-control study in the 
United States and Canada that began in 1976. Cases of birth defects are ascertained from 
birth hospitals, tertiary care centers, or birth defects registries in Massachusetts(1976+); 
Philadelphia, PA(1976+); San Diego, CA(2001+); Toronto, Canada(1976–2005); selected 
counties in Iowa(1983–1985); and parts of New York State(2004+). Cases include 
livebirths, fetal deaths(1990+), and elective terminations(1990+). Controls are liveborn 
infants selected from study hospitals and birth certificates of the catchment area from which 
cases were collected. Prior to 1993, controls consisted of infants with minor malformations, 
such as heart murmurs and skin tags. Beginning in 1993, non-malformed infants were used. 
The study has been approved by the Boston University Institutional Review Board and is in 
compliance with the Health Insurance Portability and Accountability Act.
A maternal interview is conducted by a trained nurse within six months of delivery among 
subjects providing informed consent. The interview includes questions on reproductive 
history, medication use and illnesses during pregnancy. Beginning in 1988, data on diet 
were collected using a food frequency questionnaire (FFQ).
The present study includes cases of spina bifida and controls ascertained between 1976 
through 2011. Spina bifida cases were excluded in the presence of chromosomal anomalies, 
Mendelian inherited disorders, recognized syndromes, amniotic bands, body wall defects, or 
conjoined twins. Cases were reviewed by a clinical geneticist and classified into isolated and 
multiple defect categories. Cases were considered multiple if another major defect, unrelated 
to spina bifida, was present.
Diabetes and Obesity
Information on diabetes, both preexisting and gestational, was collected throughout all years 
of the study. Preexisting diabetes was defined as the onset of type 1 or type 2 diabetes prior 
to pregnancy. Gestational diabetes was defined as the onset of diabetes after the first lunar 
month of the index pregnancy. Body mass index (BMI) was calculated based on the 
mother’s self-reported height and prepregnancy weight. Data on BMI were available from 
1993 onwards when information on maternal height was incorporated into the interview. 
BMI was categorized into four groups; underweight (<18.5 kg/m2), normal-weight (18.5–
24.9 kg/m2), overweight (25– 29.9 kg/m2), and obese (≥30 kg/m2)20.
Folic Acid Intake Assessment
Folic acid intake in the periconceptional period, defined as the month prior to the last 
menstrual period through the first lunar month of pregnancy, was calculated by summing 
average daily folic acid intake from supplements and fortified foods. Natural folate from diet 
was also included, but discounted by 30% due to its lower bioavailability6. Data on dietary 
intake was collected from an adapted Willett FFQ. The FFQ asked about diet in the six 
months prior to pregnancy to best capture nutritional intake in the periconceptional period. 
Dietary values of folic acid and folate were adjusted for total energy intake using the 
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residual method21. Subjects were categorized into two groups, those achieving the 
recommended intake of ≥400µg /day of folic acid (high intake) and those with an intake of 
<400 µg/day (low intake). Subjects with extreme caloric intake (<500 or >4,000 kcal/day) 
and incomplete (≥3 missing items) FFQs were excluded from analyses involving folic acid 
intake; however, two exceptions were made. Women reporting ≥400µg of daily folic acid 
from vitamin supplementation remained in the analysis, because regardless of dietary intake 
they would be included in the ≥400µg/day category. Secondly, women reporting no 
supplementation remained in the analysis because regardless of dietary intake it is unlikely 
they would reach ≥400µg/day of folic acid9. Women with missing information on diet and 
an intake of <400µg/day from supplementation were excluded.
Statistical Analyses
Logistic regression models were used to calculate odds ratios and 95% confidence intervals 
(95%CI). We calculated crude and adjusted odds ratios (cOR and aOR, respectively) for the 
associations between spina bifida and preexisting diabetes and gestational diabetes, 
separately. To assess the joint effect of low folic acid intake on the association between 
preexisting diabetes and spina bifida, subjects were categorized into four unique groups; (1) 
no diabetes and ≥400µg/day folic acid (referent), (2) diabetes and ≥400µg/day of folic acid, 
(3) no diabetes and <400µg/day of folic acid, and (4) diabetes and <400µg/day of folic acid. 
The relative excess risk due to interaction (RERI) and 95% CI between diabetes and low 
folic acid intake was calculated. Women with gestational diabetes were excluded from the 
analysis of joint effect.
Analyses in which BMI was assessed were restricted to 1993–2011 birth years and excluded 
women with preexisting diabetes. We calculated odds ratios for underweight, overweight, 
and obese groups. To assess the joint effect of low folic acid intake and obesity, subjects 
were categorized into four unique groups; (1) normal-weight and ≥400µg/day of folic acid 
(referent), (2) obese and ≥400µg/day of folic acid, (3) normal-weight and <400µg/day of 
folic acid, and (4) obese and <400µg/day of folic acid. The RERI and 95% CI was 
calculated. BMI data were missing for 2.5% percent of participants and missing BMI did not 
appear to be independent of other analytic variables. Therefore, we conducted a sensitivity 
analysis in which multiple imputation methods were used to impute BMI; the impact of 
using these imputed values to estimate the association between BMI and spina bifida was 
assessed. Due to changes in case and control ascertainment over the study period, a 
sensitivity analysis to address the possibility of selection bias was performed by restricting 
cases and controls to those from the same birth hospitals. Maternal age, education, race, 
study site, and folic acid intake (<400µg/day, ≥400µg/day) were included in regression 
models to adjust for potential confounding. Joint effect models did not include folic acid 
intake as a covariate. Analyses were performed using SAS software 9.3.
Results
Diabetes
A total of 1,154 cases of spina bifida and 9,439 controls ascertained between 1976 through 
2011 were included in the diabetes analysis. Cases and controls differed byrace/ethnicity, 
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maternal age, education, and folic acid intake (Table 1). Among case mothers, the 
prevalence of preexisting diabetes was 0.69% compared to 0.44% among control mothers. 
The aOR for preexisting diabetes and spina bifida was 1.84 (95% CI:0.80, 4.22); that for 
gestational diabetes was 1.19 (95% CI:0.84, 1.71)(Table 2). Spina bifida in the presence of 
other defects had an aOR of 2.56 (95% CI:0.59, 11.13) for preexisting diabetes, while that 
for isolated spina bifida was 1.70 (95% CI:0.68, 4.29)(data not shown).
The joint effect of low folic acid intake and preexisting diabetes resulted in 4-fold increased 
risk for spina bifida (aOR:3.95, 95%CI:1.56,10.00) relative to mothers without diabetes and 
with higher daily folic acid intake, which was greater than expected given the individual 
additive effects of low folic acid intake and preexisting diabetes (RERI:1.65, 95% CI:
2.87,6.18). In the presence of ≥400µg/day of folic acid, this association was attenuated 
(aOR:1.31, 95% CI: 0.17, 10.30), although this estimate was based on one exposed case 
(Table 3).
Sensitivity analyses restricted to cases and controls from the same birth hospitals changed 
diabetes results modestly, but the RERI still indicated synergy between diabetes and low 
folic acid intake (data not shown).
Obesity
Restrictions to the years in which data on BMI were available and exclusion of women with 
preexisting diabetes yielded a total of 389 cases and 8062 controls in the BMI analysis. 
During this time period, cases and controls differed by maternal age, education and folic 
acid intake (Table 1). Among case mothers, 19.0% were obese compared to 10.8% of 
control mothers. The aOR for spina bifida among overweight women was 1.24 (95% CI:
0.93, 1.63); that for obese women was 1.97 (95% CI:1.46, 2.65) (Table 4). Overall, 4.37% of 
cases and 2.44% of controls were missing data on BMI, with Hispanic mothers more likely 
to have missing BMI data (15.8% of cases and 9.4% of controls) (data not shown). Multiple 
imputation of BMI did not materially change the results (Table 4).
There did not appear to be a joint effect between obesity and folic acid intake (RERI: 0.14, 
95% CI: 1.08, 1.35). With normal-weight and higher folic acid intake as the referent, the 
aOR for obesity and low folic acid intake was 2.43 (95%CI: 1.63, 3.63), which is expected 
under the assumption of independent additive associations of obesity and low folic acid 
intake (Table 5).
Obesity results remained unchanged when restricted to cases and controls from the same 
birth hospitals (data not shown).
Comment
Failure to achieve the recommended intake of folic acid during the periconceptional period 
is suggestive of a further increase in the risk for spina bifida among mothers with preexisting 
diabetes, while the increased risk among obese mothers was not more than expected.
We observed a two-fold increased risk of spina bifida among women with preexisting 
diabetes, but the estimate was unstable due to a small number of diabetic cases. Although 
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other studies to date have considered the relationship between preexisting diabetes and the 
combined group of all neural tube defects, including spina bifida and anencephaly, few have 
quantified the association between diabetes and spina bifida, specifically. Our odds ratio, 
based on eight exposed cases, was well above the estimates observed in two previous 
studies, which reported odds ratios of 0.4 (0–4.4) and 0.75 (0.17–3.24)22,23, but was smaller 
in magnitude than that reported from a cohort study in Nova Scotia (RR: 17.2, 2.3–128.8)24. 
Findings were similar to those from a study with an odds ratio of 1.81 (0.53–6.20) for non-
Hispanic whites25. Of note, the previous findings were each based on less than four exposed 
cases.
Our observation regarding the joint effect of folic acid intake and diabetes are consistent 
with that previously reported16. In the study by Correa et al., the odds ratio for spina bifida 
among mothers who used folic acid-containing supplements and had preexisting diabetes 
was 1.66(0.62–4.42), compatible with the 1.31(0.17–10.30) we observed. Our risk estimate 
for diabetic mothers who did not consume the recommended intake of folic acid was 
somewhat larger than the odds ratio reported for the equivalent group in that study (i.e., 
diabetics not using supplements), 3.95 and 2.37, respectively16. It should be noted that the 
previous study did not include dietary intake of folic acid and defined the window of folic 
acid intake as the month prior to conception through the first three months of pregnancy; in 
contrast, the present study included dietary intake of both synthetic folic acid and natural 
food folate and estimated daily folic acid intake during the month before and after the last 
menstrual period. The neural tube closes during the second month of pregnancy and the 
proportion of women taking supplements vastly increases during the second and third 
month, which would contribute to misclassification of folic acid intake.
The mechanism by which folic acid may reduce the risk of spina bifida due to diabetic 
embryopathy is not well understood. It has been proposed that folic acid has antioxidant 
properties that mitigate the effect of reactive oxygen species and abnormal apoptosis 
resulting from diabetes15,26,27. A potential explanation of our findings involves the ability of 
folic acid to reduce oxidative stress in the embryo caused by increased levels of glucose. 
Oxidative stress leads to reduced expression of the Pax3 gene which may result in 
malformation of the neural tube27. In addition to folic acid, other antioxidants have been 
shown to reduce the occurrence of malformations in diabetic animal models28,29.
Few studies have addressed the association between diabetes and spina bifida specifically, 
and those displayed inconsistent results; on the other hand, research on obesity and spina 
bifida is more abundant and results more consistent. Data from the present investigation are 
consistent with previously published studies reporting odds ratios ranging from 1.5 to 
3.510,12 contributing to the growing body of evidence supporting a two-fold increase in the 
risk of spina bifida among obese women.
The risk of spina bifida among obese women achieving the recommended intake of folic 
acid was comparable with the risk among obese women who did not consume the 
recommended amount. This finding is consistent with a previous study, based on the same 
data source in a different time period as the present study, that observed that 400µg/day of 
folic acid was not protective against neural tube defects among heavier women, defined as 
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>70 kg17. In a study comparing risks of neural tube defects by maternal weight categories in 
pre-fortification and post-fortification time periods, the reduction in risk was lowest among 
women in the highest weight quartile30. Serum folate levels have been shown to be lower 
among obese women, even after controlling for folic acid intake31. It has been estimated that 
obese women need to consume an additional 350µg/day of folic acid to achieve the same 
serum levels of folate as women in the lowest BMI category31.
Strengths of this study are the large sample size and the amount of diabetic cases, more than 
in previous studies. Another strength of this study is the short interval between delivery and 
interview. The short time period between delivery and interview likely improved the 
mothers’ reporting accuracy. Lastly, we were able to include both diet and supplements in 
the calculation of folic acid intake. The FFQ asked about diet in the six months prior to the 
last menstrual period, which is likely reflective of diet in early pregnancy and neural tube 
development. Furthermore, dietary data were available from a validated FFQ and the Slone 
Birth Defect Study has a comprehensive database of supplement information which 
improved classification of folic acid in specific supplement products over time.
Despite these strengths, some limitations should be considered when interpreting the results. 
Data on preexisting diabetes and obesity were collected by maternal report, which may have 
resulted in misclassification. The prevalence of previously diagnosed diabetes among 
women aged 20–39, from 1988–1994, was 1.1%32. The reported prevalence of preexisting 
diabetes among control mothers in our study was 0.44%. The estimated prevalence of 
prepregnancy obesity in the U.S. from 1993 to 2003 ranges from 13–22%33. In the present 
study, the prevalence among controls was 11%. In addition to underreporting, time trends 
and demographic differences may explain some of the discrepancy between published 
prevalences of diabetes and obesity and those reported in our study. Observed associations 
would have been attenuated if misclassification of preexisting diabetes and obesity was 
similar for cases and controls.
A limitation that may have affected our findings regarding diabetes, folic acid, and spina 
bifida is lack of information of glycemic control. Enhanced glycemic control during 
pregnancy reduces the rate of birth defects to levels similar to the general population34–36. 
Additionally, diabetic women who achieve glycemic control are more likely to have 
preconception care and subsequently more likely to take folic acid supplements37. We could 
not determine if the observed reduction in risk was due to higher folic acid intake or to 
glycemic control. Another limitation of the diabetes analysis was lack of data on BMI prior 
to 1993, making it infeasible to include BMI in the multivariate analyses for all study years. 
However, pre-pregnancy weight was available for all years of the study, and a sub-analysis 
adjusting for pre-pregnancy weight yielded comparable results (data not shown). 
Additionally, we lacked dietary data prior to 1988. However, it is expected that the 
contribution of diet to overall folic acid intake would be low prior to fortification.
In summary, achieving the daily recommended intake of ≥400µg of folic acid reduced the 
risk of spina bifida, yet this level of intake had a greater effect on reducing the risk of spina 
bifida due to diabetes than that due to obesity. An understanding of the mechanism by which 
diabetes appears to increase the risk for spina bifida and how folic acid may reduce its 
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teratogenicity would provide more insight into whether or not higher levels of folic acid 
intake has the potential to further attenuate the risk of spina bifida due to obesity.
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Table 3
The Joint Effect of Folic Acid Intake and Diabetes and the Risk of Spina Bifida, Slone Birth Defects Study, 
1976–2011
Preexisting
Diabetes
<400 µg
Folic Acid Ca/Co aORa (95% CI)
No No 242/3827 1.0 (ref)
No Yes 803/4798 1.99 (1.69, 2.34)
Yes No 1/15 1.31 (0.17, 10.30)
Yes Yes 7/24 3.95 (1.56, 10.00)
RERI (95% CI): 1.65 (−2.87, 6.18)
aOR: adjusted odds ratio; CI: confidence interval; RERI: relative excess risk due to interaction
aAdjusted for maternal age, education, race/ethnicity, and study center
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Table 5
The Joint Effect of Folic Acid Intake and Obesity and the Risk of Spina Bifida, Slone Birth Defects Study, 
1993–2011
Obese
< 400 µg
Folic
Acid Ca/Co aORa (95% CI)
No No 80/2494 1.0 (ref)
No Yes 102/2333 1.22 (0.89, 1.68)
Yes No 23/340 2.08 (1.27, 3.39)
Yes Yes 48/506 2.43 (1.63, 3.63)
RERI (95% CI): 0.14 (−1.08, 1.35)
aOR: adjusted odds ratio; CI: confidence interval; RERI: relative excess risk due to interaction
aAdjusted for maternal age, education, race/ethnicity, and study center
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